XIAOMING JIA to Risk Factors
This is a "connection" page, showing publications XIAOMING JIA has written about Risk Factors.
Connection Strength
0.970
-
Association of interleukin-6 and interleukin-18 with cardiovascular disease in older adults: Atherosclerosis Risk in Communities study. Eur J Prev Cardiol. 2023 11 09; 30(16):1731-1740.
Score: 0.082
-
PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance. Vasc Health Risk Manag. 2022; 18:555-566.
Score: 0.075
-
Midlife determinants of healthy cardiovascular aging: The Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis. 2022 06; 350:82-89.
Score: 0.074
-
Association of patient, provider and facility related characteristics with statin associated side effects and statin use: Insight from the Veteran's Affairs healthcare system. J Clin Lipidol. 2021 Nov-Dec; 15(6):832-839.
Score: 0.071
-
Association between circulating Galectin-3 and arterial stiffness in older adults. Vasa. 2021 Nov; 50(6):439-445.
Score: 0.070
-
Plasma Dehydroepiandrosterone Sulfate and Cardiovascular Disease Risk in Older Men and Women. J Clin Endocrinol Metab. 2020 12 01; 105(12).
Score: 0.067
-
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date. Vasc Health Risk Manag. 2020; 16:1-10.
Score: 0.063
-
Highlights from Selected Cardiovascular Disease Prevention Studies Presented at the 2019 European Society of Cardiology Congress. Curr Atheroscler Rep. 2019 11 19; 21(12):46.
Score: 0.062
-
High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study. Circulation. 2019 06 04; 139(23):2642-2653.
Score: 0.060
-
Eligibility and Cost for Icosapent Ethyl Based on the REDUCE-IT Trial. Circulation. 2019 03 05; 139(10):1341-1343.
Score: 0.059
-
Poststatin Lipid Therapeutics: A Review. Methodist Debakey Cardiovasc J. 2019 Jan-Mar; 15(1):32-38.
Score: 0.058
-
The CHA2DS2-VASc score: Not as simple as it seems. Int J Cardiol. 2018 04 15; 257:92-96.
Score: 0.056
-
GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
Score: 0.055
-
Early-onset atherosclerotic cardiovascular disease. Eur J Prev Cardiol. 2025 Jan 27; 32(2):100-112.
Score: 0.022
-
Prevalence and Predictors of Premature Coronary Heart Disease Among Asians in the United States: A National Health Interview Survey Study. Curr Probl Cardiol. 2023 Jul; 48(7):101152.
Score: 0.018
-
Social Determinants of Health and Comorbidities Among Individuals with Atherosclerotic Cardiovascular Disease: The Behavioral Risk Factor Surveillance System Survey. Popul Health Manag. 2022 02; 25(1):39-45.
Score: 0.017
-
Soluble Angiotensin-Converting Enzyme 2, Cardiac Biomarkers, Structure, and Function, and Cardiovascular Events (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2021 05 01; 146:15-21.
Score: 0.017
-
Performance of High-Sensitivity Cardiac Troponin Assays to Reflect Comorbidity Burden and Improve Mortality Risk Stratification in Older Adults With Diabetes. Diabetes Care. 2020 06; 43(6):1200-1208.
Score: 0.016
-
Estimates of radiation exposure and subsequent risk of malignancy due to cardiac imaging in the emergency department for evaluation of chest pain: a cohort study. Coron Artery Dis. 2019 Dec; 30(8):626-628.
Score: 0.016
-
Risk Assessment of Stroke in Patients with Atrial Fibrillation: Current Shortcomings and Future Directions. Cardiovasc Drugs Ther. 2019 02; 33(1):105-117.
Score: 0.015